TRACON PHARMACEUTICALS INC (TCON) Stock Analyst Earnings Estimates
NASDAQ:TCON - Nasdaq - US89237H3084 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 346K | -100.00% | 12.045M | -100.00% | 1.19M | 24.676M 1,973.61% | 73.18M 196.56% | 125.81M 71.92% | 178.67M 42.02% | 248.26M 38.95% | 314.46M 26.67% | |
| EBITDA YoY % growth | -28.333M -74.78% | -27.878M 1.61% | -6.884M 75.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -28.347M -74.73% | -27.894M 1.60% | -6.898M 75.27% | -14.933M -116.48% | -17.745M -18.83% | -4.133M 76.71% | 16.427M 497.42% | 71.438M 334.88% | 132.52M 85.50% | 176.1M 32.89% | 231.67M 31.56% | |
| Operating Margin | -8,192.77% | N/A | -57.27% | N/A | -1,491.14% | -16.75% | 22.45% | 56.78% | 74.17% | 70.93% | 73.67% | |
| EPS YoY % growth | -1.69 22.12% | -1.40 17.16% | 10.04 817.14% | -4.26 -142.40% | -2.92 31.39% | 0.04 101.40% | -0.38 -1,025.00% | -0.31 18.92% | N/A | N/A | N/A |
All data in USD
| Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|
| EPS Q2Q % growth | -1.43 -132.61% | -0.41 -107.03% | -1.02 -610.00% |
| Revenue Q2Q % growth | -100.00% | 1.02M | |
| EBITDA Q2Q % growth | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.513M -197.69% | -2.758M 23.12% | -4.196M -1,131.03% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2024 Q2Q % growth | -1.33 -269.44% | -1.21 | -0.12 | -9.57% |
| Q4 2023 Q2Q % growth | 0.20 164.52% | -1.63 | 1.83 | 112.25% |
| Q3 2023 Q2Q % growth | 5.80 2,033.33% | -1.33 | 7.13 | 537.41% |
| Q2 2023 Q2Q % growth | 4.40 1,519.35% | -2.04 | 6.44 | 315.69% |
| Q1 2023 Q2Q % growth | -0.36 25.00% | -0.27 | -0.09 | -35.75% |
| Q4 2022 Q2Q % growth | -0.31 22.50% | -0.28 | -0.03 | -12.56% |
| Q3 2022 Q2Q % growth | -0.30 21.05% | -0.29 | -0.01 | -4.11% |
| Q2 2022 Q2Q % growth | -0.31 46.55% | -0.38 | 0.07 | 18.41% |
| Q1 2022 Q2Q % growth | -0.48 -45.45% | -0.43 | -0.05 | -12.72% |
| Q4 2021 Q2Q % growth | -0.40 -29.03% | -0.36 | -0.04 | -11.14% |
| Q3 2021 Q2Q % growth | -0.38 | -0.33 | -0.05 | -14.88% |
| Q2 2021 Q2Q % growth | -0.58 17.14% | -0.32 | -0.26 | -82.59% |
| Q1 2021 Q2Q % growth | -0.33 57.69% | -0.31 | -0.02 | -6.08% |
| Q4 2020 Q2Q % growth | -0.31 75.20% | -0.41 | 0.10 | 25.14% |
| Q3 2020 Q2Q % growth | -0.38 77.65% | -0.66 | 0.28 | 42.68% |
| Q2 2020 Q2Q % growth | -0.70 66.67% | -0.74 | 0.04 | 5.56% |
| Q1 2020 Q2Q % growth | -0.78 67.50% | -1.16 | 0.38 | 32.48% |
| Q4 2019 Q2Q % growth | -1.25 | -1.70 | 0.45 | 26.40% |
| Q3 2019 Q2Q % growth | -1.70 | -2.09 | 0.39 | 18.70% |
| Q2 2019 Q2Q % growth | -2.10 | -1.94 | -0.16 | -8.36% |
| Q1 2019 Q2Q % growth | -2.40 | -2.14 | -0.26 | -12.04% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | 3.045M | 1.02M | -1.02M | -100.00% |
| Q3 2023 Q2Q % growth | 3.621M | -3.621M | -100.00% | |
| Q2 2023 Q2Q % growth | 9M | 2.295M | 6.705M | 292.16% |
| Q2 2022 Q2Q % growth | -100.00% | % | ||
| Q4 2021 Q2Q % growth | 58.283K | -58.283K | -100.00% | |
| Q3 2021 Q2Q % growth | 58.283K | -58.283K | -100.00% | |
| Q1 2019 Q2Q % growth | 4.335M | -4.335M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -2457.58% | 0% | -943.33% |
| Revenue | N/A | N/A | N/A | N/A |